Leerink Swann &Amp; Company Initiates Coverage of Taro Pharmaceutical Industries Ltd. (NASDAQ: TARO)
Posted on: Wednesday, 18 January 2006, 12:00 CST
This morning, Senior Specialty Pharmaceuticals Analyst, William F. Sawyer, initiated coverage of Taro Pharmaceutical Industries Ltd (NASDAQ: TARO) with a Market Perform rating. Mr. Sawyer rates Taro Market Perform because of the unpredictability of its generics business at this time due to possible continued wholesaler de-stocking and increased competition within the generic topicals market. He also believes current consensus estimates may be overly optimistic. Longer-term, he believes Taro's eventual participation in the generic injectables market could enable solid revenue and EPS growth.
About Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries (NASDAQ: TARO) develops, manufactures, and markets high-quality branded and generic pharmaceutical products. Its prescription and over-the-counter medications are used primarily in dermatology, pediatrics, cardiology and neurology. The company is headquartered in Yakum, Israel.
About Leerink Swann & Company
Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2005 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. Through its internal team of experts and its dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann & Company is a member NASD/SIPC.
Contact: John I. Fitzgerald Leerink Swann & Company (617) 918-4564 www.leerink.com
SOURCE: Leerink Swann & Co.
Source: MARKET WIRE
Related Articles
- Research and Markets: This Essential Report Comprehensively Examines the Indian Pharmaceutical Industry
- 'Conservative' Pharmaceutical Industry Slow to Take Advantage of Online Marketing Opportunities
- Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry Report Now Available
- Research and Markets: The Evolving Strategies of Generics Company Teva and the Growing Acceptance of Generic Drugs in Japan, Read More Inside 'State of the Pharmaceutical Industry, 2007'
- Teva Pharmaceutical Industries, Ltd. (TEVA) President, CEO, CFO and Chairman of the Board to Ring the NASDAQ Stock Market Opening Bell
- Research and Markets: European Countries Look Set To Overtake The United States In Their Implementation Of Prospective Payment Systems for the Pharmaceutical Industry
- Examine Global Trends in the Pharmaceutical Industry - Pharmaceuticals - Global Outlook 2006
- A Look and the Current and Future Market for the Pharmaceutical Industry in The UK
- Research and Markets: Project Management for the Pharmaceutical Industry
 |
 |
User Comments (0)
RSS Feeds